National patterns and predictors of liver biopsy use for management of hepatitis C

Journal of Hepatology

Volumn 57, Issue 2, 2012, Pages 252-259

  Groessl, Erik J ^a,b   Liu, Lin ^b   Ho, Samuel B ^a,b   Kanwal, Fasiha ^g,h   Gifford, Allen L ^c,d   Asch, Steven M ^e,f  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VA St Louis ^*  (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Guidelines; Hepatitis C; Liver biopsy

Indexed keywords

ANTIVIRUS AGENT;

AGE; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; DISABILITY; ETHNICITY; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER BIOPSY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE; TREATMENT CONTRAINDICATION;

BIOPSY; HEPATITIS C; HUMANS; LIVER; LOGISTIC MODELS; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84863989152     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.03.021     Document Type: Article

References (37)

1. M.J. Alter, D. Kruszon-Moran, O.V. Nainan, G.M. McQuillan, F. Gao, and L.A. Moyer The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
2. J. Dominitz, E.J. Boyko, T.D. Koepsell, P. Heagerty, C. Maynard, and J.L. Sporleder Prevalence of hepatitis C in veterans: results of VA cooperative study #488 Gastroenterology 126 2004 A672
3. CDC Center for Disease Control: recommendations for prevention and control of HCV infection and HCV-related chronic disease Morbidity Mortality Weekly Rep 47 1998 1 10
4. CDC CfDC Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease Morbidity Mortality Weekly Rep 47 1998 1 39
5. T. Heintges, and J.R. Wands Hepatitis C virus: epidemiology and transmission Hepatology 26 1997 521 526
6. M.W. Fried, and S.J. Hadziyannis Treatment of chronic hepatitis C infection with peginterferons plus ribavirin Semin Liver Dis 24 Suppl 2 2004 47 54
7. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
8. T. Burney, and G. Dusheiko Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients Expert Rev Anti-infect Ther 9 2011 151 160
9. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
10. H.S. Yee, S.L. Currie, J.M. Darling, and T.L. Wright Management and treatment of hepatitis C viral infection: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program office Am J Gastroenterol 101 2006 2360 2378
11. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
12. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
13. M. Persico, S. Perrotta, E. Persico, L. Terracciano, A. Folgori, and L. Ruggeri Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years J Viral Hepat 13 2006 290 296
14. G. Pasquale, E. Sagnelli, N. Coppola, F. Scarano, C. Scolastico, and P.F. Bellomo Is liver biopsy necessary for hepatitis C virus carriers with persistently normal aminotransferase levels? Eur J Gastroenterol Hepatol 15 2003 831 833
15. C. Puoti, L. Bellis, and R. Guarisco Liver biopsy in hepatitis C virus carriers with normal alanine aminotransferase levels Hepatology 50 2009 655
16. K. Baicker, A. Chandra, J.S. Skinner, and J.E. Wennberg Who you are and where you live: how race and geography affect the treatment of medicare beneficiaries Health Aff (Millwood) Suppl. Web Exclusives 2004 VAR33 VAR44
17. J. Skinner, J.N. Weinstein, S.M. Sporer, and J.E. Wennberg Racial, ethnic, and geographic disparities in rates of knee arthroplasty among medicare patients N Engl J Med 349 2003 1350 1359
18. J.O. Smith, and R.K. Sterling Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C Aliment Pharmacol Ther 30 2009 557 576
19. T. Poynard, F. Imbert-Bismut, M. Munteanu, D. Messous, R.P. Myers, and D. Thabut Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C Comp Hepatol 3 2004 8
20. B. Kronenberger, and S. Zeuzem Current and future treatment options for HCV Ann Hepatol 8 2009 103 112
21. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
22. M.B. Wilck, M.B. Hamel, and L.R. Baden Clinical decisions. Management of incidental hepatitis C virus infection - polling results N Engl J Med 360 2009 e30
23. F. Kanwal, T. Hoang, B.M. Spiegel, S. Eisen, J.A. Dominitz, and A. Gifford Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors Hepatology 46 2007 1741 1749
24. S.B. Ho, E. Groessl, A. Dollarhide, S. Robinson, D. Kravetz, and E. Dieperink Management of chronic hepatitis C in veterans: the potential of integrated care models Am J Gastroenterol 103 2008 1810 1823
25. G. Usluer, N. Erben, N. Aykin, O. Dagli, O. Aydogdu, and S. Barut Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C Eur J Clin Microbiol Infect Dis 2012 [Epub ahead of print]
26. V. Calvaruso, and A. Craxi Of the study of the liver hepatitis C virus clinical practice guidelines Liver Int 32 Suppl. 1 2012 2 8
27. M. Lai, and N.H. Afdhal Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade Am J Gastroenterol 106 2011 2121 2122
28. J.M. Sutherland, E.S. Fisher, and J.S. Skinner Getting past denial - the high cost of health care in the United States N Engl J Med 361 2009 1227 1230
29. J.E. Wennberg Practice variation: implications for our health care system Managed care (Langhorne, Pa) 13 2004 3 7
30. L.I. Backus, D.B. Boothroyd, B.R. Phillips, and L.A. Mole Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus J Viral Hepat 13 2006 799 810
31. J.D. Birkmeyer, S.M. Sharp, S.R. Finlayson, E.S. Fisher, and J.E. Wennberg Variation profiles of common surgical procedures Surgery 124 1998 917 923
32. Y. Song, J. Skinner, J. Bynum, J. Sutherland, J.E. Wennberg, and E.S. Fisher Regional variations in diagnostic practices N Engl J Med 363 2010 45 53
33. J.E. Wennberg Unwarranted variations in healthcare delivery: implications for academic medical centres BMJ 325 2002 961 964
34. J.E. Wennberg Practice variations and health care reform: connecting the dots Health Aff (Millwood) Suppl. Web Exclusives 2004 VAR140 VAR144
35. H. Groom, E. Dieperink, D.B. Nelson, J. Garrard, J.R. Johnson, and S.L. Ewing Outcomes of a hepatitis C screening program at a large urban VA medical center J Clin Gastroenterol 42 2008 97 106
36. S.B. Ho, R.L. Gebhard, L.L. Tetrick, J.M. Durfee, N. Steinberg, and C.M. Parenti Key components and logistics of hepatitis C care within a VISN: a proposal Veterans Health Syst J 4 1999 41 55
37. J.R. Kramer, F. Kanwal, P. Richardson, M. Mei, and H.B. El-Serag Gaps in the achievement of effectiveness of HCV treatment in national VA practice J Hepatol 56 2012 320 325